| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 837-841 |
| Número de páginas | 5 |
| Publicación | Cancer Drug Resistance |
| Volumen | 4 |
| N.º | 4 |
| DOI | |
| Estado | Published - 2021 |
Nota bibliográfica
Funding Information:van Waardenburg RCAM in part funded by American Cancer Society UAB ACS-IRG Junior Faculty Development Grant (ACS-IRG-60-001-53), Department of Defense OCRP pilot award W81XWH-15-1-0198, and the National Institutes of Health Cancer Center Core Support Grant (P30CA013148) and National Institutes of Health - National Institute of Disorders and Stroke (1R21NS116312-01A1).
Financiación
van Waardenburg RCAM in part funded by American Cancer Society UAB ACS-IRG Junior Faculty Development Grant (ACS-IRG-60-001-53), Department of Defense OCRP pilot award W81XWH-15-1-0198, and the National Institutes of Health Cancer Center Core Support Grant (P30CA013148) and National Institutes of Health - National Institute of Disorders and Stroke (1R21NS116312-01A1).
| Financiadores | Número del financiador |
|---|---|
| Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council | 1R21NS116312-01A1 |
| National Institutes of Health (NIH) | P30CA013148 |
| National Institutes of Health (NIH) | |
| U.S. Department of Defense | W81XWH-15-1-0198 |
| U.S. Department of Defense | |
| American Cancer Society-Michigan Cancer Research Fund | ACS-IRG-60-001-53 |
| American Cancer Society-Michigan Cancer Research Fund |
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
